

**Table 4.** Comparative data of SHBG, total testosterone, estradiol, cFT, bioavailable testosterone and FAI within specific histological lesions of NAFLD subgroups according to NASH Clinical Research Network classification<sup>15</sup>

Histological lesion	Patients (N)	Total testosterone				Bioavailable testosterone	FAI
		SHBG (nmol/L)	Estradiol (pg/mL)	(ng/dL)	cFT (ng/dL)	(ng/dL)	
<b>Steatosis grade (p-value)*</b>		0.155	0.438	0.858	0.477	0.569	0.434
≤33%	13	36.0 (25.4-43.7)	23.8 (20.3-30.6)	19.5 (19.1-36.3)	0.46 (0.33-0.71)	11.9 (7.8-16.9)	3.1 (1.8-4.5)
>33%	9	23.2 (17.6-39.9)	22.1 (20.1-27.5)	22.2 (19.8-37.2)	0.49 (0.40-0.68)	11.8 (11.3-16.8)	3.5 (2.8-4.3)
<b>Fibrosis stage (p-value)*</b>		0.591	0.075	0.530	0.474	0.420	0.531
Absent	5	32.4 (25.6-42.4)	24.2 (23.1-32.0)	23.9 (20.0-46.8)	0.60 (0.37-0.81)	14.9 (9.1-19.1)	3.9 (2.8-4.6)
Present	17	29.0 (20.4-43.2)	22.1 (19.7-28.9)	20.3 (19.7-34.3)	0.47 (0.34-0.62)	11.4 (8.0-15.2)	3.3 (1.9-4.2)
<b>Lobular inflammation (p-value)*</b>		0.082	0.352	0.422	0.942	0.971	0.562
Absent	14	36.7 (26.2-43.6)	23.8 (20.1-30.1)	23.1 (20.8-38.5)	0.51 (0.33-0.69)	13.2 (7.8-16.4)	3.3 (1.9-4.6)
Present	8	22.3 (18.7-34.5)	22.0 (19.5-27.4)	20.8 (19.9-31.1)	0.46 (0.38-0.70)	11.4 (9.9-16.6)	3.5 (2.6-3.9)
<b>Portal inflammation (p-value)*</b>		0.833	0.151	0.247	0.291	0.259	0.324
None to minimal	11	32.1 (24.0-43.2)	24.2 (22.3-29.6)	23.9 (19.9-40.5)	0.57 (0.33-0.76)	14.1 (8.1-18.0)	3.9 (1.9-4.6)
Greater than minimal	11	29.0 (19.4-43.3)	20.1 (19.6-28.5)	20.2 (19.6-33.8)	0.45 (0.34-0.51)	11.4 (7.8-13.2)	3.2 (1.9-3.8)
<b>Ballooning (p-value)*</b>		0.421	0.367	0.649	0.366	0.365	0.421
Absent	4	35.7 (28.4-44.4)	27.0 (20.6-32.1)	28.9 (20.1-51.2)	0.73 (0.34-0.84)	17.5 (8.2-19.6)	4.4 (1.9-4.6)
Present	18	28.4 (20.9-43.1)	23.3 (20.0-28.7)	21.1 (19.7-34.0)	0.48 (0.34-0.61)	11.6 (7.9-15.1)	3.3 (1.9-4.1)

Data are presented as median (25-75 percentile)

\*: Between groups comparison (independent sample t-test or Mann-Whitney test)

cFT: calculated free testosterone; FAI: free androgen index; NAFLD: nonalcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis; SHBG: sex hormone-binding globulin